Polynucleotides encoding anti-Notch1 NRR antibody polypeptides

Patent metadata

Field	Value
Publication number	US-10005844-B2
Application number	US-201715722635-A
Country	US
Kind code	B2
Filing date	Oct 2, 2017
Priority date	Jun 4, 2007
Publication date	Jun 26, 2018
Grant date	Jun 26, 2018

Abstract

The invention provides anti-Notch1 NRR antibodies, and compositions comprising and methods of using these antibodies.

First claim

What is claimed is:

1. A polynucleotide encoding:
(a) a first polypeptide comprising a light chain variable region, wherein the light chain variable region comprises HVR-L1, HVR-L2, and HVR-L3 comprising, in order, SEQ ID NOs: 7, 8, and 9; or SEQ ID NOs: 7, 8, and 10; or SEQ ID NO: 7, 8, and 11; or SEQ ID NOs: 7, 8, and 12; or
(b) a second polypeptide comprising a heavy chain variable region, wherein the heavy chain variable region comprises HVR-H1, HVR-H2, and HVR-H3 comprising, in order, SEQ ID NOs: 1, 2, and 6; or SEQ ID NOs: 1, 3, and 6; or SEQ ID NOs: 1, 4, and 6; or SEQ ID NOs: 1, 5, and 6; or
(c) a first polypeptide comprising a light chain variable region, wherein the light chain variable region comprises HVR-L1, HVR-L2, and HVR-L3, and a second polypeptide comprising a heavy chain variable region, wherein the heavy chain variable region comprises HVR-H1, HVR-H2, and HVR-H3, wherein HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3 comprise, in order, SEQ ID NOs: 7, 8, 9, 1, 2, and 6; or SEQ ID NOs: 7, 8, 10, 1, 3, and 6; or SEQ ID NOs: 7, 8, 11, 1, 4, and 6; or SEQ ID NOs: 7, 8, 12, 1, 5, and 6.

2. An expression vector comprising the polynucleotide of claim 1 .

3. An isolated host cell comprising the polynucleotide of claim 1 , wherein the polynucleotide encodes a first polypeptide comprising a light chain variable region, wherein the light chain variable region comprises HVR-L1, HVR-L2, and HVR-L3, and a second polypeptide comprising a heavy chain variable region, wherein the heavy chain variable region comprises HVR-H1, HVR-H2, and HVR-H3, wherein HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3 comprise, in order, SEQ ID NOs: 7, 8, 9, 1, 2, and 6; or SEQ ID NOs: 7, 8, 10, 1, 3, and 6; or SEQ ID NOs: 7, 8, 11, 1, 4, and 6; or SEQ ID NOs: 7, 8, 12, 1, 5, and 6.

4. The isolated host cell of claim 3 , which is a prokaryotic host cell.

5. The isolated host cell of claim 3 , which is a eukaryotic host cell.

6. The isolated host cell of claim 5 , which is a mammalian host cell.

7. A method of producing an anti-Notch1 NRR antibody, said method comprising (a) culturing the host cell of claim 3 such that the antibody is expressed, and (b) recovering the antibody.

8. The method of claim 7 , wherein the host cell is a prokaryotic host cell.

9. The method of claim 7 , wherein the host cell is a eukaryotic host cell.

10. The method of claim 9 , wherein the host cell is a mammalian host cell.

Assignees

• Genentech Inc

Inventors

• Siebel Christian W
• Wu Yan

Classifications

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title